Se desexas distinguir vos teus produtos, servizos ou ambos os dous doutra empresa, é posible que necesites unha marca ou nome comercial. Descobre que son, en que consiste ou seu procedemento de rexistro e que implica.
Información sobre los plazos de presentación de solicitudes de transformación de marcas de la Unión Europea en marca nacional española. Más información
Se tes un novo dispositivo, produto ou procedemento que resolva un problema técnico ou teña unha vantaxe práctica, existen distintas formas de protexelo en España e noutros países. Descobre como facelo.
A túa innovación reside na estética, a ornamentación ou a aparencia do teu produto? Protéxea mediante un deseño industrial. Descobre que dereitos confire ou rexistro e como realizar a tramitación.
As indicacións xeográficas protexen o nome dun produto orixinario dunha zona xeográfica, á cal lle debe unha determinada calidade, reputación ou outra característica. Descobre que son, en que consiste o seu procedemento de rexistro e que beneficios conceden.
As patentes publicadas en todo ou mundo son unha valiosa fonte de información científica, técnica e comercial.
El Bono 3 del Fondo para PYMEs 2025, que cubre la elaboración de Informes Tecnológicos de Patentes (ITP) y Búsquedas Retrospectivas se cerrará el lunes 10 de febrero de 2025 al cierre de la jornada laboral. Próximamente se informará sobre su reapertura. Puede consultar más información aquí.
Ése emprendedor/a ou unha empresa e queres potenciar e mellorar a rendibilidade do teu negocio protexendo de forma adecuada vos activos intangibles dá túa organización, neste espazo atoparás ou necesario.
196
resultados
Última actualización
23/10/2026 [06:53:00]
Resultados 50 a 75 de 196
Resumen de: WO2026206121A1
A photoacoustic measurement device of the present invention comprises a first housing and a second housing. The first housing accommodates a light source. The second housing accommodates an ultrasonic sensor and is in acoustic contact with the first housing. The characteristic acoustic impedance of a first material constituting the first housing is greater than the characteristic acoustic impedance of a second material constituting the second housing. The first housing further includes an opening through which light generated by the light source is emitted. The second housing further includes an optical path through which the light generated by the light source is guided. The optical path of the second housing is formed in a direction in which the light travels from the opening of the first housing.
Resumen de: WO2026206023A1
Disclosed is a photoacoustic measurement method for quantitatively measuring components of a sample by using a laser pulse having a prescribed wavelength and an ultrasonic sensor having a prescribed frequency band. The photoacoustic measurement method may comprise the steps of, when the incident position of a laser pulse, the beam width of the laser pulse, and the relative position of an ultrasonic sensor are determined from the given frequency band of the ultrasonic sensor and the given position of a photoacoustic region in a sample: (a) oscillating the laser pulse with prescribed pulse energy and a prescribed pulse width to be incident onto the photoacoustic region in the sample; (b) detecting, by means of the ultrasonic sensor, photoacoustic waves generated in the photoacoustic region in the sample by the incident laser pulse, and acquiring sampling data by sampling the waveforms of the detected photoacoustic waves at a prescribed sampling rate; and (c) storing the sampling data. Furthermore, the distance from the photoacoustic region to the ultrasonic sensor may be determined on the basis of the wavelength of a frequency belonging to the frequency band of the ultrasonic sensor, and the beam width of the laser pulse may be determined on the basis of the half wavelength of the maximum frequency belonging to the frequency band of the ultrasonic sensor.
Resumen de: WO2026207251A1
The present disclosure provides systems, methods, compositions, and algorithms for treating a subject diagnosed with a glucose hypometabolic disorder (e.g., Alzheimer's disease, Parkinson's disease, or heart failure).
Resumen de: US20260295159A1
A system for pairing a controller and an infusion pump is disclosed. The system includes an infusion pump, a controller device and a user interface residing on both the infusion pump and the controller. The user interface includes a pairing mode for enabling wireless communication between the infusion pump and the controller device, wherein the user interface requires both the infusion pump and the controller to be in the pairing mode simultaneously. Also, a method of changing a power source in an infusion pump is disclosed. The method includes placing the infusion pump in idle mode wherein the infusion pump stops delivery. Removing the first power source from the infusion pump. Replacing the first power source with a second power source in the infusion pump, and maintaining the insulin on board during the changing of the first power source with the second power source.
Resumen de: US20260301941A1
0000 Methods and systems for encouraging interactions with a glucose monitoring system include incrementing a score and/or providing a reward based on a variety of different interactions with the glucose monitoring system. The interactions which improve the score may include initiating or changing displays, downloading data, setting operational parameters and other interactions that are independent of a user's glucose measurements. Encouraging these interactions can enhance success in maintaining healthy glucose concentrations.
Resumen de: US20260295074A1
0000 This disclosure relates to ribosomal remodeling due to high glucose conditions. In some embodiments, translation of proteins in pancreatic beta-cells is altered based on the ribosomal remodeling. Means of increasing the percentage of large ribosomal subunit protein P1 (RPLP1) associated with ribosomes and/or decreasing the percentage of soluble RPLP1 in a cell to counteract effects of high glucose conditions in diabetes are disclosed.
Resumen de: US20260294287A1
A continuous glucose monitor (CGM) sensor includes a glucose oxidation electrode and a counter electrode, and does not include a glucose-specific enzyme. The glucose oxidation electrode includes a nanoporous layer comprising metal nanoparticles. The CGM sensor generates an electrical signal indicative glucose oxidation in a liquid containing glucose, which has a correlation with an effective surface area of the metal nanoparticles in the nanoporous layer. When the CGM sensor is implanted in a subject's body, an AC voltage is applied between the glucose oxidation electrode and the counter electrode, and impedance is obtained. A glucose level for the subject is determined using the impedance without use of information or data related to glucose sensitivity of a sensor or sensors over use or time.
Resumen de: US20260295150A1
0000 A method for administering medicament from a medical device includes receiving, from a sensor, a first biomarker level in a user, determining a basal rate of endogenous glucose production based on one or more biomarker levels, determining, based on the basal rate, an amount of medicament to transfer to the user, transmitting a first instruction to the medical device to deliver the amount of medicament to the user, further receiving, from the sensor, a second biomarker level in the user, adjusting the basal rate based on the first biomarker level and the second biomarker level, adjusting the amount of medicament to transfer to the user based on the adjusted basal rate, and transmitting a second instruction to the medical device to deliver the amount of medicament to the user.
Resumen de: US20260294345A1
Described herein are variations of an analyte monitoring system, including an analyte monitoring device. For example, an analyte monitoring device may include an implantable microneedle array for use in measuring one or more analytes (e.g., glucose), such as in a continuous manner. The microneedle array may include, for example, at least one microneedle including a tapered distal portion having an insulated distal apex, and an electrode on a surface of the tapered distal portion located proximal to the insulated distal apex. At least some of the microneedles may be electrically isolated such that one or more electrodes is individually addressable.
Resumen de: EP4814986A2
0001 An aspect of an embodiment or partial embodiment of the present invention (or combinations of various embodiments in whole or in part of the present invention) comprises, but not limited thereto, a method and system (and related computer program product) for continually assessing the risk of hypoglycemia for a patient and then determining what action to take based on that risk assessment. A further embodiment results in two outputs: (1) an attenuation factor to be applied to the insulin rate command sent to the pump (either via conventional therapy or via open or closed loop control) and/or (2) a red/yellow/green light hypoglycemia alarm providing to the patient an indication of the risk of hypoglycemia. The two outputs of the CPHS can be used in combination or individually.
Resumen de: EP4814980A2
Disclosed are techniques, devices and systems that obtain a glucose measurement history and a liquid drug delivery history. An expected drug delivery amount may be calculated based on the obtained glucose measurement history and the obtained liquid drug delivery history. A processor may calculate a plurality of respective drug delivery amounts implemented using different advisory mode algorithms. A respective advisory drug delivery amount of the plurality of respective advisory drug delivery amounts may be selected by the processor. A recommendation may be generated based on the selected respective advisory drug delivery amount.
Resumen de: EP4813291A2
0001 Example disposable biosensor devices having an activity sensor are disclosed. One example device includes a disposable biosensor that has a first electrode having a distal end to be inserted into a subcutaneous layer beneath a person's skin, the first electrode having a reactive material disposed on the distal end, and a second electrode. The disposable biosensor device also includes an activity sensor that can be activated upon an activity by the person, the activity sensor for detecting the activity and providing data about the activity. The disposable biosensor also includes a radio frequency transmitter for transmitting data obtained from the first or second electrode and the activity sensor.
Resumen de: EP4814115A2
Disclosed are devices for determining an analyte concentration (e.g., glucose). The devices comprise a sensor configured to generate a signal associated with a concentration of an analyte and a sensing membrane located over the sensor. The sensing membrane comprises a biointerface layer which interfaces with a biological fluid containing the analyte to be measured. The biointerface layer comprises a biointerface polymer, wherein the biointerface polymer comprises polyurethane and/or polyurea segments and one or more zwitterionic repeating units. The biointerface layer increases sensor longevity and decrease sensor inaccuracy by inhibiting accumulation of cells, proteins, and other biological species on the outermost layers of the sensor.
Resumen de: US12745932B1
An electrode system for an electrochemical sensor, such as a glucose sensor, is disclosed. The electrode system may include a working electrode, a reference electrode, and a counter electrode. The working electrode may comprise two layers of different metals, such as gold and platinum. A method for forming such an electrode system is disclosed.
Resumen de: NZ800826A
Described herein are doses and dosing regimens comprising determining and administering doses of long-acting insulin receptor agonists suitable for once-weekly dosing, such as Weekly Basal Insulin-Fc (BIF). In particular, the invention provides the use of insulin efsitora alfa/BIF for treating diabetes comprising an initial 3x loading dose followed by one or more once-weekly maintenance dose/s.
Resumen de: WO2019193351A1
There is provided inter aliaa medical infusion pump system comprising a pump and a reservoir comprising an aqueous liquid pharmaceutical composition for delivery by means of said pump to a mammal wherein the composition comprises (i) an insulin compound at a concentration of 400 U/mLor more, (ii) ionic zinc and (iii) a non-ionic surfactant and wherein the said pump delivers the composition in pulses wherein the volume of the pulse is 0.5 µLor less.
Resumen de: NZ799606A
A body-attachable unit for continuous glucose measurement that includes an upper and lower case enclosing a PCB 530, communication chip 540, battery 535, and a sensor unit 520. The sensor unit 520 can be inserted into the body. Initially, the sensor and communication chip are disconnected while the battery 535 remains connected to the PCB 530. Switching to an active state (where sensor and chip are connected) occurs when a user-intended object approaches a specific region of the unit.
Resumen de: NZ813952A
An embodiment may provide a method for calibrating sensitivity for glucose measurement including: obtaining an offset value for determining sensitivity; determining a first sensitivity from a sensor data and a reference glucose value, based on the offset value; and determining sensitivity by adjusting the first sensitivity, wherein the determining of the sensitivity includes obtaining one sensitivity, and determining sensitivity A by adjusting the one sensitivity by reflecting an average sensor data obtained by averaging a plurality of sensor data and an average glucose value obtained by averaging a plurality of glucose values to the one sensitivity; and determining the sensitivity A as the sensitivity.
Resumen de: WO2026194464A1
A glucose monitoring method, comprising: determining first information and second information, wherein the first information is a glucose monitoring result corresponding to a first time period, the second information is a target behavior type associated with the first time period, the target behavior type is one of user behavior types, and the user behavior types comprise one or more of an eating behavior type, an exercise behavior type or a sleep behavior type; and on the basis of the first information and the second information, generating first prompt information, wherein the first prompt information is used for prompting the glucose monitoring result associated with the target behavior type. The method can help a user achieve more precise and more effective glucose management.
Resumen de: WO2026198676A1
Various systems and methods are disclosed, which may implement a neural network to process a profile of a subject, time-dependent food consumption data of the subject, and time- dependent physical activity data of the subject, to predict a time-dependent blood glucose level of the subject, without measuring blood glucose levels from blood, interstitial fluid, or sweat of the subject.
Resumen de: WO2026198957A1
Citrus huanglongbing (HLB) caused by 'Candidatus Liberibacter asiaticus' (CLas) is the most devastating citrus disease worldwide. With CLas infection, RNA-seq analyses were performed on HLB-susceptible Valencia sweet orange and HLB-tolerant Sugar Belle mandarin in winter, spring, summer, and fall. CLas infection stimulates the expression of oxidative 5 stress- and cell death/survival related genes. Such genes were selected as gene editing targets, and crRNA and gRNA sequences were determined for transgene-free genome editing of the target genes to generate HLB-resistant/tolerant citrus varieties.
Resumen de: WO2026196765A1
This hemoglobin concentration measurement device comprises: a light output unit that outputs, to a living body, measurement light including at least light having a first wavelength and light having a second wavelength different from the first wavelength; a light detection unit that detects the measurement light transmitted through the living body; a signal acquisition unit that acquires, on the basis of a detection result of the light detection unit, a first signal relating to blood of the living body and a second signal relating to surrounding tissue other than the blood of the living body; and a hemoglobin concentration estimation unit that estimates a hemoglobin concentration on the basis of the first signal and the second signal acquired by the signal acquisition unit when a blood flow state of the living body is a first state, and the first signal and the second signal acquired by the signal acquisition unit when the blood flow state is a second state different from the first state.
Resumen de: WO2026197573A1
The present invention relates to: a photonic interpenetrating polymeric network structure-based glucose biosensor in which a cholesteric liquid crystal in a solid state and a cationic polymer electrolyte are combined; a manufacturing method therefor; and a skin-attachable sweat-based glucose biosensor patch comprising same. The photonic interpenetrating polymeric network structure-based glucose biosensor according to the present invention is easy to manufacture, can be manufactured as a film, can be attached to the skin, and can visually detect the glucose concentration in the body quickly and accurately using only a small amount of sweat.
Resumen de: US20260283539A1
0000 In some aspects, a computer-implemented method is disclosed for gathering and processing sensor data to identify a risk of impacting or causing a skin injury. The computer-implemented method can include: receiving, via a computer network, sensor feature data representing output of a user sensor configured to be worn on a limb of a user; generating activity classification model output data using the sensor feature data and an activity classification model, the activity classification model output data representing likelihoods that the sensor feature data corresponds to each of a plurality of different activity classifications; determining an activity classification from the activity classification model output data; and transmitting, via the computer network, display data representing the activity classification to a computing device configured to present the display data.
Nº publicación: US20260290595A1 24/09/2026
Solicitante:
DEXCOM INC [US]
Dexcom, Inc.
Resumen de: US20260290595A1
0000 Systems and methods are provided for reconciling untrusted data of a subject using trusted data pertaining to the subject. Systems and methods are directed to evaluating differences in predicted data with respect to corresponding received data. Systems and methods estimate metabolic states from a combination of trusted and untrusted metabolic inputs, along with optionally using a personalized mathematical model with parameter optimization. Systems and methods provide for reconciled untrusted inputs with their measured impact of the glycemic signals that is consistent with a metabolic model. Estimation of future metabolic states for decision support and automated insulin dosing is enabled. Replay of scenarios with estimated or reconciled data is also provided.
BOPI
Sede Electrónica
